Imipenem and relebactam pharmacokinetics in peritoneal fluid: microdialysis reveals infection-independent penetration
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01838-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Huan Tong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, Department of Pharmacy, The Third Hospital of Changsha, Changsha, People's Republ…. Hauptthemen laut MEDLINE: Imipenem, Azabicyclo Compounds, Anti-Bacterial Agents, Ascitic Fluid. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Science and Technology Department, Changsha Municipal Bureau of Science and Technology Changsha.
Abstract (Originalsprache)
Imipenem/relebactam is a promising therapy for complicated intra-abdominal infections caused by carbapenem-resistant Enterobacterales species. However, data on tissue-site pharmacokinetics are limited. We evaluated the peritoneal penetration of imipenem and relebactam in healthy and infected rats by using microdialysis. The animals received a single intravenous infusion of imipenem (45 mg/kg) and relebactam (22.5 mg/kg), and unbound concentrations were dynamically monitored in the plasma and peritoneal fluid. Imipenem exposure in the peritoneal fluid was consistently lower than that in the plasma, with peritoneal fluid-to-plasma AUC ratios of 0.29 in the control group and 0.27 in the infection group. In contrast, relebactam demonstrated nearly equivalent concentrations in both compartments, with ratios of 0.81 and 0.86, respectively. Both agents reached peak levels at 30 min, and the semi-logarithmic curves showed rapid equilibrium without delay. The partition coefficients estimated by two-compartment modeling for imipenem (0.333–0.342) and relebactam (0.679–0.816) were consistent with non-compartmental results. Infection increased the distribution volume and clearance of relebactam but did not significantly alter peritoneal permeability for either drug. These findings provide the first description of the penetration of relebactam into peritoneal fluid. Subsequent pharmacodynamic target attainment (PTA) analysis showed that under the latest EUCAST PK/PD criteria, PTA values dropped markedly to an MIC of 1 mg/L, indicating a substantially reduced probability of achieving adequate peritoneal exposure. These results highlight the need for dosing strategies to ensure sufficient peritoneal drug concentration to maintain antimicrobial efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, Department of Pharmacy, The Third Hospital of Changsha, Changsha, People's Republic of China.
- Hunan University of Chinese Medicine, Changsha, People's Republic of China.
ORCID-Profile: Changhui Deng, Xin Li
Förderung
- Hunan Provincial Science and Technology Department
- Changsha Municipal Bureau of Science and Technology Changsha
Zitieren
APA
Tong, H., Cao, Z., Li, J., Yang, H., Qiao, Y., Guo, S., Deng, C., & Li, X. (2026). Imipenem and relebactam pharmacokinetics in peritoneal fluid: microdialysis reveals infection-independent penetration. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01838-25
Vancouver
Tong H, Cao Z, Li J, Yang H, Qiao Y, Guo S, et al. Imipenem and relebactam pharmacokinetics in peritoneal fluid: microdialysis reveals infection-independent penetration. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01838-25
BibTeX
@article{Tong2026,
author = {Tong, Huan and Cao, Zekun and Li, Jiakai and Yang, Haoming and Qiao, Yong and Guo, Siwei and Deng, Changhui and Li, Xin},
title = {Imipenem and relebactam pharmacokinetics in peritoneal fluid: microdialysis reveals infection-independent penetration},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01838-25}
}
EUVIMED